Search research articles
Contact Us
Filters
Showing results (131-140 of 165) with videos related to
Page
of 17
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
February 2, 2023
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 18, 2024
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Journal for Immunotherapy of Cancer
|
February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Investigational New Drugs
|
December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
Journal of Pain and Symptom Management
|
November 22, 2023
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, et al.
JTO Clinical and Research Reports
|
February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
JAMA Oncology
|
March 18, 2021
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial
Yoshitaka Zenke, Masahiro Tsuboi, Yasutaka Chiba, et al.
International Journal of Cardiology
|
July 9, 2023
Clinical impact of optical coherence tomography findings after drug-coated balloon treatment for patients with acute coronary syndromes
Tetsuya Yamamoto, Hiroyuki Kawamori, Takayoshi Toba, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 165) with videos related to
Sort By:
Page
of 17
Lung Cancer (Amsterdam, Netherlands)
|
February 2, 2023
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 18, 2024
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Journal for Immunotherapy of Cancer
|
February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Investigational New Drugs
|
December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
Journal of Pain and Symptom Management
|
November 22, 2023
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, et al.
JTO Clinical and Research Reports
|
February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
JAMA Oncology
|
March 18, 2021
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial
Yoshitaka Zenke, Masahiro Tsuboi, Yasutaka Chiba, et al.
International Journal of Cardiology
|
July 9, 2023
Clinical impact of optical coherence tomography findings after drug-coated balloon treatment for patients with acute coronary syndromes
Tetsuya Yamamoto, Hiroyuki Kawamori, Takayoshi Toba, et al.
Page
of 17